Full Text
RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE

Abstract

Authors

Jia Hao Wong Adrien Gras Malvin Kang Taro Kanzaki

Back to Volume 49, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×